REG - Physiomics PLC - Physiomics Awarded New Contract by Numab

PhysiomicsAnnouncement

11/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251211:nRSK0906La&default-theme=true

RNS Number : 0906L  Physiomics PLC  11 December 2025

11 December 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Physiomics Awarded New Contract by Numab Therapeutics

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce a new contract with
its valued and long-standing client, Numab Therapeutics AG.

This latest project will use modelling and simulation approaches to support
the pre-clinical development of a multi-specific antibody in the Numab
Therapeutics pipeline, under development for the treatment of autoimmune
diseases. In this collaboration, Physiomics will develop a mechanistic
Pharmacokinetics and Pharmacodynamics (PK/PD) model that can be used to
inform quantitative understanding of the drug's behaviour and select
appropriate dosing for preclinical and clinical studies. The project is
expected to be delivered within the financial year ending 2026.

This new contract further emphasies the important role that Model Informed
Drug Development approaches continues to play across the drug development
lifecycle, including in the pre-clinical environment.

 

Dr Peter Sargent, CEO of Physiomics, commented:

"We are very pleased to announce a further contract with Numab Therapeutics,
one of our most valued clients, and continue to support the development of
their pipeline of therapeutic antibodies across both Oncology and Autoimmune
indications."

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTVBLFFELLBFBV



            Copyright 2019 Regulatory News Service, all rights reserved